Wealth Enhancement Advisory Services LLC Has $1.08 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wealth Enhancement Advisory Services LLC decreased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 27.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 81,247 shares of the company's stock after selling 30,452 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Takeda Pharmaceutical were worth $1,076,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TAK. Farther Finance Advisors LLC increased its position in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after acquiring an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $52,000. Cromwell Holdings LLC acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $61,000. Venturi Wealth Management LLC boosted its position in Takeda Pharmaceutical by 554.7% in the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after buying an additional 4,260 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its position in Takeda Pharmaceutical by 65.0% in the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after buying an additional 2,029 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Trading Up 1.5%

Shares of NYSE TAK traded up $0.22 during mid-day trading on Thursday, hitting $15.39. The company's stock had a trading volume of 3,026,273 shares, compared to its average volume of 1,950,895. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The stock has a market cap of $48.97 billion, a price-to-earnings ratio of 38.48, a price-to-earnings-growth ratio of 0.24 and a beta of 0.23. The company's fifty day simple moving average is $14.67 and its 200-day simple moving average is $14.13. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.